File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Nitrogen‐Containing Bisphosphonates Are Associated With Reduced Risk of Pneumonia in Patients With Hip Fracture

TitleNitrogen‐Containing Bisphosphonates Are Associated With Reduced Risk of Pneumonia in Patients With Hip Fracture
Authors
KeywordsANTIRESORPTIVES
EPIDEMIOLOGY
GENERAL POPULATION STUDIES
OSTEOPOROSIS
Issue Date2020
PublisherWiley-Blackwell Publishing, Inc. The Journal's web site is located at http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1523-4681
Citation
Journal of Bone and Mineral Research, 2020, Epub 2020-06-02 How to Cite?
AbstractThe objective of this work was to study the risk of pneumonia and pneumonia mortality among patients receiving nitrogen‐containing bisphosphonates (N‐BPs), non‐N‐BP anti‐osteoporosis medications, and no anti‐osteoporosis medications after hip fracture. We studied a historical cohort using a population‐wide database. Patients with first hip fracture during 2005–2015 were identified and matched by time‐dependent propensity score. The cohort was followed until December 31, 2016, to capture any pneumonia and pneumonia mortality. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated using Cox‐proportional hazards regression. Absolute risk difference (ARD) and number needed to treat (NNT) were calculated. We identified 54,047 patients with hip fracture. Of these, 4041 patients who received N‐BPs and 11,802 without anti‐osteoporosis medication were propensity score–matched. N‐BPs were associated with a significantly lower risk of pneumonia compared with no treatment (6.9 versus 9.0 per 100 person‐years; HR 0.76; 95% CI, 0.70 to 0.83), resulting in an ARD of 0.02 and NNT of 46. A similar association was observed with pneumonia mortality (HR 0.65; 95% CI, 0.56 to 0.75). When N‐BPs were compared with non‐N‐BP anti‐osteoporosis medications, the association remained significant. N‐BPs were associated with lower risks of pneumonia and pneumonia mortality. Randomized controlled trials are now required to determine whether N‐BPs, non–vaccine‐based medications, can reduce pneumonia incidence in high risk groups. © 2020 American Society for Bone and Mineral Research.
Persistent Identifierhttp://hdl.handle.net/10722/283732
ISSN
2019 Impact Factor: 5.854
2015 SCImago Journal Rankings: 2.773

 

DC FieldValueLanguage
dc.contributor.authorSing, CW-
dc.contributor.authorKiel, DP-
dc.contributor.authorHubbard, RB-
dc.contributor.authorLau, WCY-
dc.contributor.authorLi, GHY-
dc.contributor.authorKung, AWC-
dc.contributor.authorWong, ICK-
dc.contributor.authorCheung, CL-
dc.date.accessioned2020-07-03T08:23:19Z-
dc.date.available2020-07-03T08:23:19Z-
dc.date.issued2020-
dc.identifier.citationJournal of Bone and Mineral Research, 2020, Epub 2020-06-02-
dc.identifier.issn0884-0431-
dc.identifier.urihttp://hdl.handle.net/10722/283732-
dc.description.abstractThe objective of this work was to study the risk of pneumonia and pneumonia mortality among patients receiving nitrogen‐containing bisphosphonates (N‐BPs), non‐N‐BP anti‐osteoporosis medications, and no anti‐osteoporosis medications after hip fracture. We studied a historical cohort using a population‐wide database. Patients with first hip fracture during 2005–2015 were identified and matched by time‐dependent propensity score. The cohort was followed until December 31, 2016, to capture any pneumonia and pneumonia mortality. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated using Cox‐proportional hazards regression. Absolute risk difference (ARD) and number needed to treat (NNT) were calculated. We identified 54,047 patients with hip fracture. Of these, 4041 patients who received N‐BPs and 11,802 without anti‐osteoporosis medication were propensity score–matched. N‐BPs were associated with a significantly lower risk of pneumonia compared with no treatment (6.9 versus 9.0 per 100 person‐years; HR 0.76; 95% CI, 0.70 to 0.83), resulting in an ARD of 0.02 and NNT of 46. A similar association was observed with pneumonia mortality (HR 0.65; 95% CI, 0.56 to 0.75). When N‐BPs were compared with non‐N‐BP anti‐osteoporosis medications, the association remained significant. N‐BPs were associated with lower risks of pneumonia and pneumonia mortality. Randomized controlled trials are now required to determine whether N‐BPs, non–vaccine‐based medications, can reduce pneumonia incidence in high risk groups. © 2020 American Society for Bone and Mineral Research.-
dc.languageeng-
dc.publisherWiley-Blackwell Publishing, Inc. The Journal's web site is located at http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1523-4681-
dc.relation.ispartofJournal of Bone and Mineral Research-
dc.rightsPreprint This is the pre-peer reviewed version of the following article: [FULL CITE], which has been published in final form at [Link to final article using the DOI]. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions. Postprint This is the peer reviewed version of the following article: [FULL CITE], which has been published in final form at [Link to final article using the DOI]. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions.-
dc.subjectANTIRESORPTIVES-
dc.subjectEPIDEMIOLOGY-
dc.subjectGENERAL POPULATION STUDIES-
dc.subjectOSTEOPOROSIS-
dc.titleNitrogen‐Containing Bisphosphonates Are Associated With Reduced Risk of Pneumonia in Patients With Hip Fracture-
dc.typeArticle-
dc.identifier.emailSing, CW: cwsing@connect.hku.hk-
dc.identifier.emailLi, GHY: gloriali@hku.hk-
dc.identifier.emailKung, AWC: awckung@hku.hk-
dc.identifier.emailWong, ICK: wongick@hku.hk-
dc.identifier.emailCheung, CL: lung1212@hku.hk-
dc.identifier.authorityKung, AWC=rp00368-
dc.identifier.authorityWong, ICK=rp01480-
dc.identifier.authorityCheung, CL=rp01749-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1002/jbmr.4030-
dc.identifier.pmid32488902-
dc.identifier.scopuseid_2-s2.0-85085759344-
dc.identifier.hkuros310719-
dc.identifier.volumeEpub 2020-06-02-
dc.publisher.placeUnited States-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats